Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript Summary
Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript Summary
Net loss improved slightly to $3.2 million in Q3 2024 from $3.3 million in Q3 2023.The following is a summary of the Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript:
以下是Tenon Medical, Inc. (TNON) 2024年第三季度业绩会记录的摘要：
Financial Performance:
财务业绩：
Tenon Medical reported third quarter 2024 revenue of $887,000, a 6% decrease compared to the third quarter of 2023.
Gross profit for the third quarter of 2024 was $418,000, representing 47% of revenue.
Net loss improved slightly to $3.2 million in Q3 2024 from $3.3 million in Q3 2023.
Cash and cash equivalents as of September 30, 2024, were $9.2 million, up from $2.4 million as of December 31, 2023.
Tenon Medical报告2024年第三季度营业收入为$887,000，比2023年第三季度下降了6%。
2024年第三季度毛利润为$418,000，占营业收入的47%。
净亏损略微改善，从2023年第三季度的$330万下降至2024年第三季度的$320万。
截至2024年9月30日，现金及现金等价物为$920万，上升自2023年12月31日的$240万。
Business Progress:
业务进展：
Tenon Medical focused on building market share for the Catamaran System and securing capital for growth.
Advanced commercialization and technical progress with innovations like the new Catamaran SE, SI Joint Fusion System.
Launched pre-launch alpha clinical work for Catamaran SE with positive feedback from partner physicians.
Strengthened balance sheet with investment, resulting in $9.6 million net proceeds, used for expanding sales force and clinical studies.
Tenon Medical专注于为Catamaran系统建立市场份额并确保增长所需的资金。
爱文思控股在商业化和技术进步方面取得了进展，例如新的双体船SE和SI关节融合系统。
为双体船SE启动了预发布的alpha临床工作，得到了合作医生的积极反馈。
通过投资增强了资产负债表，导致净收益达到960万美元，用于扩展销售团队和临床研究。
Opportunities:
机会：
Enhanced market presence and sales through the introduction of the Catamaran SE and the ongoing clinical validations.
Focused on expanding into geographic regions with active recruitment and workshops for medical professionals, increasing market penetration.
通过推出双体船SE和持续的临床验证增强了市场存在感和销售。
专注于扩展到地理区域，积极招聘和举办医疗专业人员的研讨会，增加市场渗透率。
Risks:
风险：
Experienced unexpected reimbursement preauthorization headwinds which impacted revenue negatively in Q3, though anticipated improvements with coding clarity and clinical data advancements.
经历了意外的报销预授权阻力，导致第三季度的营业收入受到负面影响，尽管预计编码清晰度和临床数据进展将带来改善。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的详情，请参阅投资人关系网站。本文仅供投资者参考，不作任何指引或建议。
译文内容由第三方软件翻译。